Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

Add BPTH Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/26/2018 3:18:46 AM - Followers: 55 - Board type: Free - Posts Today: 2

Bio-path Holdings Inc.



Company description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a partial phase II combination trial (with LDAC). The interim results demonstrated 47% of the patients showed early anti-leukemic activity. 

The patient dosing trials are at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the beginning of phase 2 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive. Will the company apply for FDA acclerated status as testing is complete on 17 additional evaluable patients?

CML combination drug safety study with Sprycel (Dasatinib) for BP1001 has allegedly begun at MD Anderson but we are awaiting FDA website comfirmation of same.

Patent protection for manufacturing their neutral lipid delivery system has occurred.

Bio-Path Holdings may also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected to occur in 2018.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.

While antisense drugs fell out of favor following Gilead's failed efforts there was some renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. At the present BPTH has no partnerships with drug manufacturers.

This link to the company website describes their delivery technology:

The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising additional funds the company has 5+ million in cash.

Bio-Path Holdings does not manufacture their drugs but uses contractors.
BPTH is presently traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:!/4292/presentation/2610

Analyst target price:
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3879   snug9 Thanks for the quick education. Mt Bobster 04/26/18 11:36:48 AM
#3878   Mt Bobster, do you know the difference between Snug9 04/26/18 03:18:46 AM
#3877   Too, Now for the stratosphere projection, Ariad! A SJSTOCKSHARK 04/25/18 01:13:50 PM
#3876   Too, 1/2012 is a long way from now. SJSTOCKSHARK 04/25/18 12:16:49 PM
#3875   Any thoughts on where the stock price will too simple 04/25/18 09:38:28 AM
#3874   Crai, $50 per share would equal $550 million SJSTOCKSHARK 04/24/18 09:14:55 PM
#3873   Agreed. I would even go a step further craiviolin 04/24/18 06:31:01 PM
#3872   I am not as smart as a lot Mt Bobster 04/24/18 11:39:00 AM
#3871   Agreed. They lack focus. BPTH could make a business wordlender 04/21/18 01:28:40 PM
#3870   Snug, you absolutely hit it out of the too simple 04/20/18 04:16:51 PM
#3869   The poster presentation is a perfect Harvard Business Snug9 04/20/18 01:16:27 PM
#3868   Has recruiting has begun for the CML combination SJSTOCKSHARK 04/20/18 12:28:09 PM
#3867   Almost 50% of the shares sold yesterday were shorted. SJSTOCKSHARK 04/20/18 11:59:53 AM
#3866   PN sure knows how to kill a rally SJSTOCKSHARK 04/20/18 10:41:22 AM
#3865   Crai, I find describing shorts as Sharks offensive. SJSTOCKSHARK 04/19/18 10:08:11 PM
#3864   If I had never heard of this company Gpheart2016 04/19/18 05:58:02 PM
#3863   * * $BPTH Video Chart 04-19-18 * * ClayTrader 04/19/18 05:11:03 PM
#3862   We have been here before.....the sharks... pardon me craiviolin 04/19/18 04:50:35 PM
#3861   It is amazing to watch the tape. Anytime SJSTOCKSHARK 04/19/18 10:21:04 AM
#3860   I hope PN is selling today. Raising 3-4 SJSTOCKSHARK 04/19/18 09:32:47 AM
#3859   A press release and up nicely after hours. SJSTOCKSHARK 04/18/18 09:57:21 PM
#3858   Check the current price.... Flops 04/18/18 04:52:12 PM
#3857   No word on today's presentation? SJSTOCKSHARK 04/18/18 01:25:23 PM
#3856   That would be too simple! IMO control of SJSTOCKSHARK 04/18/18 10:47:33 AM
#3855   I wonder why a company’s like ions does too simple 04/18/18 09:49:44 AM
#3854   PN, Here is an idea! Rather than giving SJSTOCKSHARK 04/17/18 10:18:34 PM
#3853   Snug, IMO There are certainly facts to support SJSTOCKSHARK 04/17/18 07:29:21 PM
#3852   SJ, something has been eating at me. Snug9 04/17/18 05:32:03 PM
#3851   We need a new COB to put some SJSTOCKSHARK 04/17/18 12:44:32 PM
#3850   runin, I suspect no funds have been raised. SJSTOCKSHARK 04/16/18 11:15:38 PM
#3849   I can't imagine that PN was stupid enough Runninonempty 04/16/18 03:24:19 PM
#3848   At this point I really hope that BPTH craiviolin 04/16/18 02:29:55 PM
#3847   The march to below a buck continues with earnest! SJSTOCKSHARK 04/16/18 12:38:21 PM
#3846   PN nice work! SJSTOCKSHARK 04/16/18 11:36:40 AM
#3845   Blair, IMO PN gave himself options for 130,000 SJSTOCKSHARK 04/15/18 12:39:41 AM
#3843   Just got this but I am too ignorant blairsoldman 04/13/18 11:38:55 PM
#3842   PN, Nice market cap less than 20 million again. SJSTOCKSHARK 04/13/18 08:01:32 PM
#3841   Mbcrunch, the presentation is at a “scientific meeting” Gpheart2016 04/13/18 10:53:52 AM
#3840   It will be nice to hear someone other mbcrunch 04/13/18 10:14:42 AM
#3839   Do we get a PPS run up in SJSTOCKSHARK 04/12/18 11:18:20 AM
#3838   I bought 150 shares @ $2.94 US pre-market Dan Flan 04/11/18 01:27:27 PM
#3837   Snug, A good point! Everyone should have their SJSTOCKSHARK 04/11/18 09:50:32 AM
#3836   While I’m on my soap box I need Snug9 04/11/18 02:47:58 AM
#3835   SJ, you are absolutely correct! Not long Snug9 04/11/18 02:30:41 AM
#3834   I work for, what I think is safe Brettj 04/10/18 11:02:32 PM
#3833   Snug, I agree he should have been paid SJSTOCKSHARK 04/10/18 08:58:16 PM
#3832   Are you kidding me Luv and Running? Snug9 04/10/18 08:02:08 PM
#3831   Could not agree with Luv more. Everyone Runninonempty 04/10/18 05:03:54 PM
#3830   This isn’t wealth. As you all know, iloveu2 04/10/18 04:06:56 PM
#3829   HEAR! HEAR!!!!!!!! craiviolin 04/10/18 12:44:53 PM